Get started
Author

C. Yau

Observed names: Connor Yau, Yau, C., Yau, Connor
OpenAlex ID: A5126173641
Integrated genomic analyses of ovarian carcinoma
2011 · D. Bell, A. Berchuck, et al. · Nature · 116
PDF
Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial
2026 · J. Tseng, K. Dimitroff, et al. · Annals of Surgical Oncology · 1
PDF
Abstract PD10-02: I- SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant vepdegestrant monotherapy or in combination with letrozole or abemaciclib in molecularly selected patients with stage 2/3 HR+ HER2-negative breast cancer (BC)
2026 · J. Chien, R. M. Mukhtar, et al. · Clinical Cancer Research · 1
LBA15 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial
2024 · M.S. Trivedi, R.A. Shatsky, et al. · Annals of Oncology · 1
PDF
Correction: ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial
2026 · J. Tseng, K. Dimitroff, et al. · Annals of Surgical Oncology
PDF
Correction: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial
2026 · J. Tseng, K. Dimitroff, et al. · Annals of Surgical Oncology
PDF
ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial
2026 · J. Tseng, K. Dimitroff, et al. · Annals of Surgical Oncology
Abstract PD11-03: Predicting treatment outcomes in breast cancer from H&E slides using pathology foundation models with multiple instance learning
2026 · A. Sun, S. Venters, et al. · Clinical Cancer Research
Abstract PD6-09: Quantifying the Contribution of Doxorubicin and Cyclophosphamide (AC) to Pathologic Response Following Neoadjuvant Taxane Therapy: Analysis of the I-SPY2 TRIAL
2026 · D. Yee, C. Yau, et al. · Clinical Cancer Research
Abstract RF1-04: Early Adverse Symptoms Predict Response to Treatment Among Patients in the I-SPY Trial
2026 · A. Basu, S. Umashankar, et al. · Clinical Cancer Research
Abstract PS1-01-09: Real-time monitoring for drug-induced interstitial lung disease with Trastuzumab Deruxtecan and Rilvegostomig combination therapy prevents persistent, symptomatic disease: Safety insights from the I-SPY2.2 platform trial
2026 · T. Kulkarni, R. Nanda, et al. · Clinical Cancer Research
Abstract RF5-06: Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788: Results from the I-SPY2.2 trial
2026 · P. R. Pohlmann, H. S. Rugo, et al. · Clinical Cancer Research
Abstract PS1-01-05: Pneumonitis but not other immune related adverse events (irAEs) associate with pre-treatment immune signatures in early-stage breast cancer patients receiving neoadjuvant immunotherapy (IO): results from 5 IO arms in I-SPY2
2026 · D. M. Wolf, H. Rugo, et al. · Clinical Cancer Research
PS4-05-28: Impact of Neoadjuvant Endocrine Therapy on MammaPrint Index in Hormone Receptor-Positive, HER2-Negative MammaPrint Low Risk Early-Stage Breast Cancer
2026 · S. Jacob, C. Wu, et al. · Clinical Cancer Research
Abstract PD6-07: Ctdna dynamics is most predictive of response in treatment-sensitive response-predictive subtypes of breast cancer: results from the I-SPY2 trial
2026 · M. Magbanua, D. Wolf, et al. · Clinical Cancer Research
Abstract PS2-11-06: Quiescent-like phenotype characterizes treatment-resistant early-stage HER2-negative breast cancers and suggests novel therapeutic targets; analysis of over 2000 patients from the I-SPY2 trial
2026 · T. Bui, D. M. Wolf, et al. · Clinical Cancer Research
Abstract PS4-02-01: Differential early response to neoadjuvant endocrine therapy in lobular versus non-lobular breast cancer on the Endocrine Optimization Pilot (EOP) of the I-SPY2 Trial
2026 · R. Mukhtar, P. Norwood, et al. · Clinical Cancer Research
Abstract PD13-01: Site(s) of Distant Recurrence after Neoadjuvant Therapy for Patients With High-Risk Early-Stage Breast Cancer (BC): Analysis of Data from the I-SPY2 Trial
2026 · L. Huppert, C. Yau, et al. · Clinical Cancer Research
Abstract PD6-03: Validation of MRI predictive models for treatment optimization in the I-SPY 2 TRIAL
2026 · W. Li, N. Onishi, et al. · Clinical Cancer Research
Abstract PS3-07-10: Low dose (Z)-endoxifen in the I-SPY2 Endocrine Optimization Pilot
2026 · K. V. Giridhar, M. P. Goetz, et al. · Clinical Cancer Research
Abstract PS4-09-08: Expanding Diversity through Innovation: Development of the I-SPY ACCESS Initiative for the I-SPY2.2 and DCIS RECAST Clinical Trials
2026 · S. L. Horton, D. A. Idossa, et al. · Clinical Cancer Research
Abstract PS3-03-08: Initial results from RECAST DCIS: Multicenter platform trial testing active surveillance and novel endocrine therapy agents for DCIS management
2026 · K. C. Hewitt, C. Yau, et al. · Clinical Cancer Research
Breaking Universality in the Lower Order Terms in the 1-level and 2-level Density of Holomorphic Cusp Newforms
2025 · Amit, Yuval, Chen, Lucas, et al. · arXiv (Cornell University)
PDF
LBA16 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) in the neoadjuvant setting: Results from the I-SPY 2.2 trial
2024 · K. Khoury, J.L. Meisel, et al. · Annals of Oncology
PDF
Would Artificial Intelligence Methods Improve Early Diagnosis and Progress of Ovarian Cancer?
2024 · Connor Yau, Yongmei Huang · Journal of Student Research
PDF
Works count: 26
Citation count: 118
H-index: 1
I10-index: 1
Year
Topic
Type